alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
1 District Judge of the Eastern District of Louisiana, sitting

by designation. UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 00-41288

In The Matter Of: GEORGE B. MAYO, Individually doing business as Real Estate Book, doing business as MayDry, Inc., doing business as Real Estate Source; CAROLYN MAYO, Individually doing business as Real Estate Book, doing business as MayDry, Inc., doing business as Real Estate Source,

Debtors.

_________________________________________________________________ GEORGE B. MAYO, Individually doing business as Real Estate Book, doing business as MayDry, Inc., doing business as Real Estate Source; CAROLYN MAYO, Individually doing business as Real Estate Book, doing business as MayDry, Inc., doing business as Real Estate Source; MAYO, BULLARD & ASSOCIATES, a Texas Partnership; ROBIN BULLARD,

Appellees,

versus

NETWORK PUBLICATIONS, INC.,

Appellants.

Appeal from the United States District Court for the Southern District of Texas

(M-99-CV-317)

October 15, 2001

Before BARKSDALE and STEWART, Circuit Judges, and DUVAL, District

Judge 1

.2 Pursuant to 5 TH C IR . R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4.

2 PER CURIAM: 2

Pursuant to 28 U.S.C. § 1292(a), we have jurisdic tion over

this appeal. We agree with the district court that this matter

must be remanded to the bankruptcy court for further consideration

in the light of the district court’s 13 July 2000 ruling.

Therefore , this case is remanded to the district court for

further remand to the bankruptcy court.

REMANDED
Fourth Court of Appeals

San Antonio, Texas

May 29, 2014

No. 04-14-00249-CV

IN THE INTEREST OF N.M.G., A Child,

From the 131st Judicial District Court, Bexar County, Texas

Trial Court No. 2013-PA-01311

Honorable Charles E. Montemayor, Judge Presiding

ORDE R

This is an appeal in a termination case, and is therefore accelerated. Appellant’s brief 

was due May 21, 2014, but was not filed. On May 29, 2014, appellant’s appointed counsel filed 

an extension of time to file the brief stating he was unaware that he was appointed to represent 

appellant on appeal until May 28, 2014. Accordingly, he filed a motion for extension of time to 

file the brief, asking that he be permitted to file the brief on or before June 18, 2014. Given the 

circumstances, we GRANT appellant’s motion and ORDER appellant to file his brief in this 

court on or before June 18, 2014.

_________________________________

Marialyn Barnard, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 29th day of May, 2014.

___________________________________

Keith E. Hottle

Clerk of Court
Exhibit 32.1

# Written Statement of
the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. §1350

Solely
for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, we, the undersigned President and Chief Executive
Officer and Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
Company), hereby certify, based on our knowledge, that the Quarterly Report on
Form 10-Q of the Company for the quarter ended September 30, 2004 (the Report)
fully complies with the requirements of Section 13(a) of the Securities Exchange Act of
1934 and that information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

/s/ Kerry L. Woody
Kerry L. Woody  President and Chief Executive Officer

/s/ Wayne E. Larsen
Wayne E. Larsen  Vice President Law/Finance & Secretary

October 25, 2004
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.4100 Complement reagent. ( a ) *Identification.* A complement reagent is a device that consists of complement, a naturally occurring serum protein from any warm-blooded animal such as guinea pigs, that may be included as a component part of serological test kits used in the diagnosis of disease.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 2001, as amended at 66 FR 38792, July 25, 2001]
Exhibit 31.2



RULE 13a-14(a)/15d-14(a) CERTIFICATION



I, Richard Dea, Chief Financial Officer, certify that:



1.

I have reviewed this quarterly report on Form 10-QSB of InZon Corporation .



2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;



4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [omitted pursuant to extended compliance period] for the small business issuer and have:



(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;



(b)  [omitted pursuant to extended compliance period]



(c) Evaluated the effectiveness of the small business issuers disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(d) Disclosed in this report any change in the small business issuers internal control over financial reporting that occurred during the small business issuers most recent fiscal quarter (the small business issuers fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuers internal control over financial reporting; and



5.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuers auditors and the audit committee of the small business issuers board of directors (or persons performing the equivalent functions):



(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuers ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuers internal control over financial reporting.



|                    |                                     
|------------------- | ------------------------------------
|Dated: May 10, 2007 | By: /s/ Richard Dea                 
|                    | Richard Dea, Chief Financial Officer
I 

118TH CONGRESS 

1ST SESSION H. R. 76 

To amend title XXVII of the Public Health Service Act to provide for 

a definition of short-term limited duration insurance, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 9, 2023 

Mr. BIGGS introduced the following bill; which was referred to the Committee 

on Energy and Commerce 

A BILL 

To amend title XXVII of the Public Health Service Act 

to provide for a definition of short-term limited duration 

insurance, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Health Coverage 

5 Choice Act’’. 

6 SEC. 2. DEFINITION OF SHORT-TERM LIMITED DURATION 

7 INSURANCE. 

8 Section 2791(b) of the Public Health Service Act (42 

9 U.S.C. 300gg–91(b)) is amended by adding at the end the 

10 following new paragraph: 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 76 IH

1 ‘‘(6) SHORT-TERM LIMITED DURATION INSUR2 ANCE.—The term ‘short-term limited duration insur3 ance’ means health insurance coverage provided 

4 under a contract with a health insurance issuer 

5 that— 

6 ‘‘(A) has an expiration date specified in 

7 the contract that is less than 12 months after 

8 the original effective date of the contract; and 

9 ‘‘(B) has a duration of not more than 3 

10 years (taking into account renewals or exten11 sions) after the original effective date of the 

12 contract.’’. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
FINANCIAL STATEMENTS INCLUDED IN FORM 10-QSB AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                         602,167
<SECURITIES>                                         0
<RECEIVABLES>                                6,941,405
<ALLOWANCES>                                 4,966,183
<INVENTORY>                                    728,601
<CURRENT-ASSETS>                             3,438,019
<PP&E>                                       2,185,343
<DEPRECIATION>                                 432,664
<TOTAL-ASSETS>                              18,010,077
<CURRENT-LIABILITIES>                        4,369,532
<BONDS>                                      8,488,801
<PREFERRED-MANDATORY>                          768,619
<PREFERRED>                                          0
<COMMON>                                    18,854,973
<OTHER-SE>                                (14,471,848)
<TOTAL-LIABILITY-AND-EQUITY>                18,010,077
<SALES>                                     10,595,943
<TOTAL-REVENUES>                            10,656,415
<CGS>                                        7,782,283
<TOTAL-COSTS>                               11,986,737
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             727,826
<INCOME-PRETAX>                            (1,988,530)
<INCOME-TAX>                                   111,862
<INCOME-CONTINUING>                        (2,100,392)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,100,392)
<EPS-PRIMARY>                                   (2.38)
<EPS-DILUTED>                                   (2.38)
        

</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.2720 Plasma oncometer for clinical use. ( a ) *Identification.* A plasma oncometer for clinical use is a device intended to measure plasma oncotic pressure, which is that portion of the total plasma osmotic pressure contributed by protein and other molecules too large to pass through a specified semipermeable membrane. Because variations in plasma oncotic pressure are indications of certain disorders, measurements of the variations are useful in the diagnosis and treatment of these disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 60 FR 38900, July 28, 1995; 66 FR 38788, July 25, 2001]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM PIMCO
ADVISORS HOLDINGS L.P. FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                              22
<SECURITIES>                                         0
<RECEIVABLES>                                   33,007
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                33,029
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 492,312
<CURRENT-LIABILITIES>                           31,653
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       460,659<F1>
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   492,312
<SALES>                                              0<F2>
<TOTAL-REVENUES>                                41,463
<CGS>                                                0<F2>
<TOTAL-COSTS>                                        0<F2>
<OTHER-EXPENSES>                                 7,690
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 33,773
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             33,773
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    33,773
<EPS-BASIC>                                       0.69
<EPS-DILUTED>                                     0.66
<FN>
<F1>Entity is a partnership. Amount shown represents Partners' Capital.
<F2>The partnership is in the service business and has no sales or cost of good
sold on tangible products.
</FN>


</TABLE>
I 

118TH CONGRESS 

2D SESSION H. R. 7657 

To direct the Secretary of Veterans Affairs to revise a certain directive 

of the Veterans Health Administration of the Department of Veterans Affairs. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 13, 2024 

Mr. FINSTAD introduced the following bill; which was referred to the 

Committee on Veterans’ Affairs 

A BILL 

To direct the Secretary of Veterans Affairs to revise a certain 

directive of the Veterans Health Administration of the 

Department of Veterans Affairs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Healthcare Freedom 

5 for VHA Volunteer Drivers Act of 2024’’. 

6 SEC. 2. REVISION TO CERTAIN DIRECTIVE OF VETERANS 

7 HEALTH ADMINISTRATION OF DEPARTMENT 

8 OF VETERANS AFFAIRS REQUIRED. 

9 (a) IN GENERAL.—The Secretary of Veterans Affairs 

10 shall revise VHA Directive 1193.01(1) titled ‘‘Coronavirus 


ddrumheller on DSK120RN23PROD with BILLS
2 

•HR 7657 IH

1 Disease 2019 Vaccination Program for Veterans Health 

2 Administration Health Care Personnel’’ and published on 

3 January 27, 2022 (as amended on December 1, 2022) to 

4 ensure that a covered individual may, subject to such con5 ditions as the Secretary determines appropriate, volunteer 

6 to transport a veteran to a medical facility of the Depart7 ment of Veterans Affairs for the purposes of receiving 

8 health care. 

9 (b) COVERED INDIVIDUAL DEFINED.—In this sec10 tion, the term ‘‘covered individual’’ means an individual 

11 who has not received a vaccination against COVID–19. 

Æ 


ddrumheller on DSK120RN23PROD with BILLS
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Centers for Disease Control and Prevention

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 75 FR 7489-7490, dated February 19, 2010) is amended to reflect the reorganization of the Office of Compensation Analysis and Support, Office of the Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

*Section C-B, Organization and Functions, is hereby amended as follows:*

Delete in its entirety the title and mission statement for the Office of Compensation Analysis and Support (CCA2) and insert the following:

Division of Compensation Analysis and Support (CCN). (1) Conducts a program in support of Federal rulemaking to promulgate science-based methods and guidelines mandated by the Energy Employees Occupational Illness Compensation Program Act of 2000 (known as the “Act”) to estimate the occupational radiation doses of claimants under the Act and evaluate the relationship between such doses and cancers incurred by the claimants; (2) develops and implements a program of science-based analysis and policymaking by which the Secretary of Health and Human Services shall consider and issue determinations on petitions by classes of employees to be included as members of the Special Exposure Cohort established under the Act; and (3) conducts a program of individual dose reconstruction to estimate and report the radiation doses of claimants under the Act.

 Dated: February 23, 2010.

William P. Nichols,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2010-4543 Filed 3-4-10; 8:45 am]

BILLING CODE 4163-18-M
818 _ 

OFFICE OF THE ATTORNEY GENERAL OF TEXAS 

AUSTIN 

Honorable JOI. B4 Dart 

Couatr Attorney 

Kendall COuMJ 

Boerne, Texae 

Thin 18 in reply to yo 

“Our County Judge, X0 

arked ,m to advire him 

‘“Ire have vithln t 

Iudependent Sohoo 

ehlldren of tranr 

rohool build1 

that ‘. . . pubahall be approeduaation alike 

en, and lmpartlal proboth raaes* Ilo phite 

oola rupported for 

11 any oolored abildrupported for VhiIte ohlldren. 

1 provider that *Every child in 

raholartia age rh8u tta permitted 

to attend the publia free rohool8 of the dl8- 

trlot or independent dlrtrlot in vhlah it ro8ide8,at the time it applier for adlU.t88iOn, 

. . . 
819 

Honorable Jar. B. Dart, pag8 2 

“tit. 2902 &WOVi&O8 th8t ‘All dill&en, vlthout regard to oolor, over 8iX year8 of age and 

undel lgbteen r year8 of age at the beginning of 

any 8ohOlaltiO year, 8hall be inoluded in the 

rcholartio Cen8U8 and 8hall be entitled to the 

benefit OS the publio rohool fund for that 

year* . . .* 

'I am unable to find any deoision8 bearing 

on the qwrtlon, and haQe aooordingly advised 

the County Judge that prOQi8iM must be made to 

take care 0r the80 10urnegr0e8~ 

“lflll you klndl~ advise ne if, in your oplnion, my advlcr is oorreot?’ 

You have oorrootly quoted the pertlnent part8 of 

the Texa8 rtatutea oonaorning thfr Quertion, and, therefore, 

VI Vill. not repeat there dXtUtO8. 

Under the aboQo rtatUte8, it 18 OUl' Opinion that 

you haoo oorrectly advlsod Judge Balrer. This oonolurlon 

18 also supported by the foll~ing authoritiera 

Hill8 v. Board of Education of AnmArundol 

County, 30 Fed. Supp. 245; 

208. 

Mlrsouri ex rel Gainer Q. Canada, 83 L. Ed. 

Very truly four8 

ATTOIUYEY GEUISAL OF TgMs 

UJF,db
# C_2014085EN.01001701.xml

| 22.3.2014 | EN | Official Journal of the European Union | C 85/17 |
| --- | --- | --- | --- |

22.3.2014

EN

Official Journal of the European Union

C 85/17

---

Request for a preliminary ruling from the Conseil d’État (France) lodged on 20 January 2014 — Union des syndicats de l'immobilier (UNIS) v Ministre du travail, de l’emploi, de la formation professionnelle et du dialogue social, Syndicat national des résidences de tourisme (SNRT) and Others

(Case C-25/14)

2014/C 85/30

Language of the case: French

Referring court

Referring court

Conseil d’État

Parties to the main proceedings

Parties to the main proceedings

Applicant: Union des syndicats de l'immobilier (UNIS)

Applicant:

Defendants: Ministre du travail, de l’emploi, de la formation professionnelle et du dialogue social, Syndicat national des résidences de tourisme (SNRT) and Others

Defendants:

Question referred

Question referred

Is compliance with the obligation of transparency flowing from Article 56 TFEU a mandatory prior condition for the extension, by a Member State, to all undertakings within a sector, of a collective agreement under which a single operator, chosen by the social partners, is entrusted with the management of a compulsory supplementary social security scheme for employees?

---
**Exhibit 32****Certifications Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)**     The undersigned, as the President and Chief Executive Officer, and Executive Vice Presidentand Chief Financial Officer of Exide Technologies, each certify that     (1) the accompanying Quarterly Report on Form 10-Q for the period ended September 30, 2006,fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the SecuritiesExchange Act of 1934, as amended; and     (2) the information contained in the periodic report fairly presents, in all materialrespects, the financial condition and results of operations of Exide Technologies at the dates andfor the periods indicated.     A signed original of this written statement required by Section 906 has been provided to ExideTechnologies and will be retained by Exide Technologies and furnished to the Securities andExchange Commission or its staff upon request.     The undersigned expressly disclaims any obligation to update the foregoing certificationexcept as required by law.Date:November 9, 2006     /S/ Gordon A. Ulsh     Gordon A. Ulsh  President and Chief Executive Officer     /S/ Francis M. Corby, Jr.     Francis M. Corby, Jr.  Executive Vice President and  Chief Financial Officer
44